Form D · Biotechnology
Phio Pharmaceuticals Corp.
King Of Prussia, PA · CIK 0001533040
Offering snapshot reported Nov 12, 2025 · SEC filing
- Reported sold
- $1.42M Offering amount: $25.9M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 4, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 12, 2025 | Initial | $1,415,796 | No comparison | 5 | SEC filing |
| Aug 4, 2025 | Initial | $232,149 | No comparison | 2 | SEC filing |
| Jan 28, 2025 | Initial | $265,918 | No comparison | 4 | SEC filing |
| Jan 28, 2025 | Initial | $152,500 | No comparison | 4 | SEC filing |
| Jan 28, 2025 | Initial | $208,334 | No comparison | 4 | SEC filing |
| Jan 7, 2025 | Initial | $30,000 | No comparison | 4 | SEC filing |
| Jan 3, 2025 | Initial | $54,649 | No comparison | 4 | SEC filing |
| Jul 24, 2024 | Initial | $136,322 | No comparison | 8 | SEC filing |
| Dec 19, 2023 | Initial | $532,563 | No comparison | 4 | SEC filing |
| Jun 13, 2023 | Initial | $2,999,373 | No comparison | 3 | SEC filing |
| May 2, 2023 | Initial | $4,010,519 | No comparison | 3 | SEC filing |
| Nov 23, 2022 | Initial | $1,750 | No comparison | 1 | SEC filing |
| Feb 16, 2021 | Initial | $14,001,909 | No comparison | 14 | SEC filing |
| Apr 14, 2020 | Initial | $4,375,011 | No comparison | 10 | SEC filing |
| Feb 24, 2020 | Initial | $1,903,128 | No comparison | 6 | SEC filing |
| Aug 17, 2018 | Amendment | $1,937,904 | $1,676,904vs Aug 18, 2017 | 1 | SEC filing |
| Aug 18, 2017 | Initial | $261,000 | No comparison | 1 | SEC filing |
| Mar 26, 2013 | Initial | $23,628,750 | No comparison | 35 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.12M
- Finders' fees
- $0
- Form D file number
- 021-563765
The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b).
$1,116,497.82 in cash and warrants to purchase up to 424,739 shares of common stock (4,500 with an exercise price of $2.8125, 71,145 with an exercise price of $3.1488, 349,094 with an exercise price of $2.875).
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co, LLC | 375 |
Source: Form D, filed Nov 12, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert J. Bitterman | Director, Executive |
| Patricia A. Bradford | Director |
| Keith Brownlie | Director |
| Lisa Carson | Executive |
| Geert Cauwenbergh | Director |
| David H. Deming | Director |
| Gerrit Dispersyn | Director, Executive |
| H. Paul Dorman | Director |
| Paul Dorman | Director |
| H Paul Dorman | Director |
| Alexey Eliseev | Executive |
| Robert Ferrara | Director |
| Jonathan Freeman | Director |
| Robert Infarinato | Executive, Promoter |
| Caitlin Kontulis | Executive |
| Curtis A Lockshin | Director |
| Curtis Lockshin, Ph.D. | Director |
| Pamela Pavco | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
411 Swedeland Road Suite 23 1080
King Of Prussia, PA, 19406
King Of Prussia, PA, 19406